一项应用促性腺激素释放激素激动剂或其拮抗剂治疗不明原因不孕和/或轻度精子减少症夫妇的前瞻性随机对照研究

作     者：Zikopoulos K. Kaponis A. Adonakis G. 李跃萍 

作者机构：Centre for Rep roductive Medicine Dept. of Obstetrics and Gynecology Ioannina Univ. School of Medicine Panepistimiou Av. 45500 Ioannina Greece Dr. 

出 版 物：《世界核心医学期刊文摘（妇产科学分册）》 (Core Journal in Obstetrics/Gynecology)

年 卷 期：2005年第1卷第9期

页      面：10-10页

学科分类：1002[医学-临床医学] 100211[医学-妇产科学] 10[医学] 

主　　题：精子减少症 拮抗剂 控制性超排卵 黄体中期 人工受精 促性腺激素 前瞻性随机试验 激动剂 释放激素 西曲瑞克 

摘      要：Objective: To compare the efficacy of GnRH antagonist vs. GnRH agonist adminis tration for controlled ovarian hyperstimulation (COH) in assisted reproduction. Design: A prospective, randomized trial. Setting: Clinical research unit at a te rtiary care medical center. Patient(s): Sixty-five patients with unexplained in fertility or mild male subfertility undergoing COH for IUI. Intervention(s): Twe nty-nine women (group A) were randomized to receive 600 μg of busereline aceta te per day starting in the midluteal phase of the cycle (long protocol), whereas 36 women (group B) were treated with 0.25 mg/d of the GnRH antagonist Cetroreli x starting from day 6 of the cycle. The starting dose of recombinant FSH was 150 IU in women of both groups. Insemination was performed 34 hours after hCG injec tion. Main Outcome Measure(s): Clinical and successful ongoing pregnancy rate (P R), measurements of serum FSH, LH, E2, and P, number of recruited follicles, dur ation of stimulation period, and amount of gonadotropins used. Result(s): Women in group A required significantly more days of treatment (median: 12.0 vs. 9.0) and significantly more total units of recombinant FSH (median 1,800 vs. 1,550) a s compared with the corresponding values of the antagonist group (group B). Seru m FSH, LH, E2, and P were significantly higher on the antagonist group on days 2 and 6 of stimulation. However, these differences regress until the day of hCG a dministration. Conclusion(s): The GnRH antagonists have facilitated short and si mple treatment, and are particularly attractive for administration in women unde rgoing COH, achieving comparable PR with the long protocol regimen.